AstraZeneca, facing lung cancer challenge from J&J, touts life-extension benefit for Tagrisso combo
21st July 2025 Uncategorised 0Following an FDA approval last year based on a tumor progression benefit, AstraZeneca said Monday that its Tagrisso combination with chemotherapy extended patients’ lives compared with Tagrisso alone in first-line EGFR-mutated NSCLC.
More: AstraZeneca, facing lung cancer challenge from J&J, touts life-extension benefit for Tagrisso combo
Source: fierce